Study details
Enrolling now
Neutralizing Interleukin (IL)-6
Icahn School of Medicine at Mount Sinai
NCT IDNCT07493317ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Ages
18–70
Locations
1 site in NY
About this study
This Phase 2 study is testing Tocilizumab in people with depression.
Based on ClinicalTrials.gov records.
PhasePhase 2
DrugTocilizumab
Routeinfusion
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low11%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
tocilizumab (Monoclonal antibody; blocks IL-6 receptor to reduce inflammation)
Drug routes
infusion
Endpoints
Secondary: Change in Montgomery-Asberg Depression Rating Scale (MADRS)
Body systems
Psychiatry / Mental Health